Abstract 41P
Background
Triple-negative breast cancer (TNBC) is associated with more aggressive disease and worse survival compared to other breast cancer subtypes. We aim to analyze the role of oncogenic mir-223 as a possible negative driving factor in TNBC through its prognostic value and association with unfavorable clinicopathologic characteristic.
Methods
We retrospectively analyzed the association of pre-treatment mir-223 expression with clinicopathologic characteristics and 3-years overall survival (OS) of Indonesian TNBC patients treated in a tertiary center during 2014-2017. Cytokeratin5/6 (CK5/6) and Epidermal Growth Factor Receptor (EGFR) expressions were examined using immunohistochemistry by 2 independent blinded pathologists. Mir-223 level of tumor tissue was measured using Real-Time qRT-PCR. Cutoff value for mir-223 was determined using Receiver Operating Curve (ROC). Chi-square and Fisher’s exact tests were used to analyze the association between categorical variables, while Kaplan-Meier curve was used to perform survival analysis.
Results
Fifty-three stage I-IV TNBC patients were included in the analysis. The mean age of our patients was 51.3 years old. Early stage, locally advanced stage, and metastatic disease respectively were found in 7 (13.2%), 38 (71.7%), and 8 (15.1%) patients. The optimal cutoff value for mir-223 was 23.435 (AUC: 0.706, 95%CI: 0.565-0.848; p: 0.01; Sensitivity: 78.6%; Specificity: 56%) and was used to classify mir-223 expression into over- and under-expressed groups. Mir-223 overexpression was associated with increased expression of EGFR (69.7% vs. 35%, p: 0.022) and lower 3-years OS (33.3% vs. 70%; mean OS±SE (months): 25.66±1.58 vs. 30.23±1.99; p log rank: 0.029). No significant association was observed between mir-223 expression with other clinicopathologic characteristics (age, BMI, stage, tumor size, nodal status, distant metastasis, and CK5/6 expression).
Conclusions
Pre-treatment mir-223 level of expression in Indonesian TNBC patients is correlated with poor survival through increase of EGFR expression. Thus, targeting mir-223 becomes a potential therapeutic strategy for TNBC patients. However, further study is needed to validate this result.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
434P - Pan-Canadian evidence-based, consensus-driven cancer treatment protocols/information for use at the point of care by medical oncologists? Is there a need?
Presenter: Kiran Virik
Session: e-Poster Display Session
435P - Hypnotics and risk of cancer: A meta-analysis of observational studies
Presenter: Tzu Rong Peng
Session: e-Poster Display Session
436P - Clinicopathological characteristics and outcomes of adolescent and young adult (AYA) melanoma: Results from an Asian perspective
Presenter: Wei Lin Goh
Session: e-Poster Display Session
437P - Long-term efficacy and toxicity outcome of adjuvant external beam radiotherapy for medullary thyroid cancer: A single institution cohort study
Presenter: Ka Man Cheung
Session: e-Poster Display Session
438P - Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma
Presenter: Carolina Ortiz Velez
Session: e-Poster Display Session
439P - Immunohistochemical analysis of p53 and Ki-67 in glioblastoma (GBM) and their correlations with patient survival
Presenter: Paulo Luz
Session: e-Poster Display Session
440P - Blinded independent central review of oncology trials: The monitoring of readers' performance
Presenter: Hubert Beaumont
Session: e-Poster Display Session
441P - Influence of radiation therapy of patients with somatotropic pituitary adenomas depending on the age of patients
Presenter: Saodat Issaeva
Session: e-Poster Display Session
442P - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Presenter: Bhumsuk Keam
Session: e-Poster Display Session